|
Cyclo Therapeutics, Inc. (Cyth) DCF -Bewertung
US | Healthcare | Drug Manufacturers - Specialty & Generic | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Cyclo Therapeutics, Inc. (CYTH) Bundle
Entdecken Sie die finanziellen Aussichten von Cyclo Therapeutics, Inc. (Cyth) mit unserem benutzerfreundlichen DCF-Taschenrechner! Geben Sie Ihre Annahmen in Bezug auf Wachstum, Margen und Kosten ein, um den inneren Wert von Cyclo Therapeutics, Inc. (Cyth) zu berechnen und Ihre Anlageentscheidungen zu informieren.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0 | .9 | 1.6 | 1.4 | 1.1 | 1.2 | 1.2 | 1.3 | 1.4 | 1.5 |
| Revenue Growth, % | 0 | -10.31 | 75.54 | -13.24 | -21.76 | 7.56 | 7.56 | 7.56 | 7.56 | 7.56 |
| EBITDA | -7.4 | -8.9 | -14.3 | -15.6 | -20.0 | -1.2 | -1.2 | -1.3 | -1.4 | -1.5 |
| EBITDA, % | -733.23 | -990.58 | -899.88 | -1134.09 | -1860.9 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 0.56404 | 1.41 | 1.06 | 1.42 | 1.79 | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 |
| EBIT | -7.4 | -9.0 | -14.3 | -15.6 | -20.1 | -1.2 | -1.2 | -1.3 | -1.4 | -1.5 |
| EBIT, % | -733.8 | -991.99 | -900.94 | -1135.51 | -1862.69 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 2.8 | 12.8 | 16.6 | 1.5 | 9.2 | 1.2 | 1.2 | 1.3 | 1.4 | 1.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .2 | .1 | .5 | .1 | .1 | .2 | .2 | .2 | .2 | .2 |
| Account Receivables, % | 18.12 | 12.37 | 34 | 4 | 11.37 | 15.97 | 15.97 | 15.97 | 15.97 | 15.97 |
| Inventories | .2 | .2 | .2 | .3 | .3 | .2 | .3 | .3 | .3 | .3 |
| Inventories, % | 24.09 | 26.34 | 14.34 | 18.5 | 23.63 | 21.38 | 21.38 | 21.38 | 21.38 | 21.38 |
| Accounts Payable | 3.1 | 3.5 | 3.7 | 2.2 | 4.9 | 1.2 | 1.2 | 1.3 | 1.4 | 1.5 |
| Accounts Payable, % | 310.24 | 391.98 | 231.94 | 162.38 | 451.18 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | -.1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | -0.13145 | -5.88 | -1.42 | -1.1 | -0.22482 | -1.75 | -1.75 | -1.75 | -1.75 | -1.75 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -7.5 | -8.9 | -14.3 | -15.4 | -20.1 | -1.2 | -1.2 | -1.3 | -1.4 | -1.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -4.8 | -8.5 | -14.6 | -16.4 | -17.5 | -4.9 | -1.2 | -1.3 | -1.4 | -1.5 |
| WACC, % | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 | 4.9 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -9.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -2 | |||||||||
| Terminal Value | -52 | |||||||||
| Present Terminal Value | -41 | |||||||||
| Enterprise Value | -50 | |||||||||
| Net Debt | -8 | |||||||||
| Equity Value | -42 | |||||||||
| Diluted Shares Outstanding, MM | 16 | |||||||||
| Equity Value Per Share | -2.58 |
What You Will Get
- Comprehensive CYTH Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed in real-time.
- Scenario Analysis: Evaluate various scenarios to assess Cyclo Therapeutics’ future outlook.
- User-Friendly Interface: Designed for professionals but easy to navigate for newcomers.
Key Features
- 🔍 Real-Life CYTH Financials: Pre-filled historical and projected data for Cyclo Therapeutics, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Cyclo Therapeutics’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Cyclo Therapeutics’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- 1. Access the Model: Download and open the Excel template featuring Cyclo Therapeutics, Inc. (CYTH) preloaded data.
- 2. Modify Key Inputs: Adjust essential variables such as growth projections, discount rates, and capital investments.
- 3. Instant Result Generation: The DCF model automatically computes intrinsic value and net present value (NPV).
- 4. Explore Different Scenarios: Evaluate various forecasts to understand diverse valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation findings to enhance your decision-making process.
Why Choose This Calculator for Cyclo Therapeutics, Inc. (CYTH)?
- Accurate Data: Up-to-date financials from Cyclo Therapeutics ensure dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations remove the hassle of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Investors: Evaluate Cyclo Therapeutics’ valuation before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and validate financial forecasts.
- Startup Founders: Understand the valuation processes of biotech companies like Cyclo Therapeutics.
- Consultants: Provide comprehensive valuation analyses for clients in the healthcare sector.
- Students and Educators: Utilize current data to learn and teach valuation strategies in biotechnology.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Cyclo Therapeutics, Inc. (CYTH).
- Real-World Data: Cyclo Therapeutics' historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics.
- Dashboard with Visual Outputs: Graphs and tables presenting clear, actionable results for informed decision-making.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.